Radiomics features based on automatic segmented MRI images: Prognostic biomarkers for triple-negative breast cancer treated with neoadjuvant chemotherapy
Authors:
- 1 January 2022
- journal article
- research article
- Published by Elsevier in European Journal of Radiology
- Vol. 146, 110095
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Radiomics Signature on Magnetic Resonance Imaging: Association with Disease-Free Survival in Patients with Invasive Breast CancerClinical Cancer Research, 2018
- Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patientsBMC Cancer, 2018
- Adjuvant Capecitabine for Breast Cancer after Preoperative ChemotherapyNew England Journal of Medicine, 2017
- Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast CancerClinical Cancer Research, 2016
- Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 StudyJournal of Clinical Oncology, 2015
- Impact of Neoadjuvant Chemotherapy in Stage II–III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation RatesAnnals of Surgery, 2015
- Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosisBreast Cancer Research, 2011
- Triple-Negative Breast CancerNew England Journal of Medicine, 2010
- Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro StudyJournal of Clinical Oncology, 2010
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast CancerJournal of Clinical Oncology, 2008